First Time Loading...

DiaMedica Therapeutics Inc
NASDAQ:DMAC

Watchlist Manager
DiaMedica Therapeutics Inc Logo
DiaMedica Therapeutics Inc
NASDAQ:DMAC
Watchlist
Price: 2.59 USD 2.37% Market Closed
Updated: May 2, 2024
Section:
 

Wall Street
Price Targets

DMAC Price Targets Summary
DiaMedica Therapeutics Inc

Wall Street analysts forecast DMAC stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for DMAC is 7.14 USD with a low forecast of 6.06 USD and a high forecast of 8.4 USD.

DMAC Lowest Forecast
Wall Street Target
6.06 USD
134% Upside
DMAC Average Forecast
Wall Street Target
7.14 USD
176% Upside
DMAC Highest Forecast
Wall Street Target
8.4 USD
224% Upside
Lowest
Price Target
6.06 USD
134% Upside
Average
Price Target
7.14 USD
176% Upside
Highest
Price Target
8.4 USD
224% Upside

DMAC Last Price Targets
DiaMedica Therapeutics Inc

The latest public price target was made on Mar 21, 2024 by Alex Nowak from Craig-Hallum , who expects DMAC stock to rise by 209% over the next 12 months. You can read more about this price target by viewing the article on StreetInsider.

Analyst Price Target Date Article
Alex Nowak
Craig-Hallum
8 USD
Upside 209%
1 month ago
Mar 21, 2024
DiaMedica Therapeutics Inc. (DMAC) PT Lowered to $8 at Craig-Hallum
StreetInsider
Alex Nowak
Craig-Hallum
Price Target 8 USD
Upside/Downside 209%
View Source
DiaMedica Therapeutics Inc Competitors:
Price Targets
688319
Chengdu Olymvax Biopharmaceuticals Inc
169% Upside
BIOA B
BioArctic AB
86% Upside
ASND
Ascendis Pharma A/S
30% Upside
S
688336
Sunshine Guojian Pharmaceutical Shanghai Co Ltd
38% Upside
688319
Chengdu Olymvax Biopharmaceuticals Inc
169% Upside
BIOA B
BioArctic AB
86% Upside
ASND
Ascendis Pharma A/S
30% Upside
S
688336
Sunshine Guojian Pharmaceutical Shanghai Co Ltd
38% Upside
688366
Shanghai Haohai Biological Technology Co Ltd
35% Upside
C
CBUS
Cibus Inc
37% Upside
PSTX
Poseida Therapeutics Inc
416% Upside
PHM
Pharma Mar SA
74% Upside

Revenue
Forecast

Revenue Estimate
DiaMedica Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
DiaMedica Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-1%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
DiaMedica Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-54%
Average Miss
What are analyst estimates?

See Also

Summary
DMAC intrinsic value, competitors valuation, and company profile.
DCF Valuation
DMAC stock valuation using Discount Cash Flow valuation method.
Relative Valuation
DMAC stock valuation using valuation multiples.
Wall Street Estimates
DMAC price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
DMAC stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is DMAC's stock price target?
Price Target
7.14 USD

According to Wall Street analysts, the average 1-year price target for DMAC is 7.14 USD with a low forecast of 6.06 USD and a high forecast of 8.4 USD.

ALPHA SPREAD
Join more than 133,400+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.